Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

IBSA

Status and phase: Terminated; Phase 4

Conditions: Congenital Hypothyroidism

Treatments: Drug: Levothyroxine Sodium; Drug: Tirosint®-SOL

Study type: Interventional

Funder types: Industry

Identifiers

NCT05228184

20US-T414

Details and patient eligibility

About

This is a multi-center, prospective, parallel-group, open-label, randomized clinical study in one hundred and twenty-six (126) neonates and infants diagnosed with CH.

Subjects will be randomized in a 2:1 ratio to Treatment (Tirosint®-SOL) or Control (conventional therapy with levothyroxine sodium crushed tablets).

Full description

Newly diagnosed neonates will be randomly assigned to start therapy with LT4 at the initial dose recommended by the Standard of Care (SOC). Infants already on LT4 therapy will continue at the same daily dose within the randomly assigned treatment group (dose adjustments are allowed, if needed based on laboratory parameters and clinical response). Once enrolled, subjects will be treated and followed for 12 months (±1.5 months), participating in 7-8 study visits, consisting of 6-7 inclinic and 1-2 (or more if follow-up visits are required) telemedicine (TM) visits. The total number of visits depends on the age at inclusion.

Enrollment: 34 patients

Sex: All

Ages: 1 day to 9 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patient aged 0 to 9 months

• Primary CH diagnosis with elevated TSH and low or normal FT4, requiring treatment with LT4, under either of the following conditions:

  • Neonates newly diagnosed with primary CH and needing to initiate LT4 therapy, or
  • Infants previously diagnosed with primary CH and who are already on LT4 therapy for at least 3 weeks;

• Provide and comply with the informed consent.

Exclusion criteria

• Preterm neonates with a gestational age < 37 weeks;

• Low birth weight (LBW) or very low birth weight (VLBW) neonates (weight < 2.5 kg) or VLBW infants (weight < 1.5 kg);

• Neonates in neonatal intensive care units or requiring admission to NICU or neonates/infants hospitalized or requiring hospitalization or in fragile health conditions (e.g. with serious health problems or complications);

• Neonates with CH diagnosis > 4 weeks after delivery;

• Diagnosis of primary gastrointestinal disease:

  • Gastroesophageal reflux requiring medical therapy (beyond thickening of formula or position);
  • Anatomic defects (e.g. intestinal atresia, malrotation, tracheoesophageal fistula, pyloric stenosis, Hirschsprung's disease, gastroschisis);
  • Dietary allergy (e.g. cow's milk protein allergy);
  • Malabsorption related to cystic fibrosis, celiac disease and others;
  • Necrotizing enterocolitis requiring surgical resection;

• Known or suspected adrenal insufficiency (e.g. congenital adrenal hyperplasia, hypopituitarism);

• Diagnosis of congenital cardiac disease, cardiac insufficiency or risk for cardiac failure;

• Diagnosis of chromosomopathy;

• Diagnosis of central hypothyroidism;

• Hypersensitivity to glycerol;

• Concomitant anticonvulsant medications, liothyronine, combination of LT4 and liothyronine, thyroid extracts and/or chronic or long-term use of systemic glucocorticoids

• History of nonadherence with medication or medical visit schedule; or

• Any condition for which, participation would not be in the best interest of the patient or that could limit protocol specified assessments.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

34 participants in 2 patient groups

Treatment

Experimental group

Description:

Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.) at the following strengths: 13, 25, 37.5, 44, 50, 62.5, 75, 88, 100 mcg.

Treatment:

Drug: Tirosint®-SOL

Control

Active Comparator group

Description:

Crushed levothyroxine sodium tablets

Treatment:

Drug: Levothyroxine Sodium